Skip to main content
Fig. 3 | Lipids in Health and Disease

Fig. 3

From: Lipid alterations play a role in the integration of PD-1/PD-L1 inhibitors and anlotinib for the treatment of advanced non–small-cell lung cancer

Fig. 3

Lipid identification in advanced NSCLC patients in the SD group. The lipid composition in the SD group samples before and after administering anlotinib along with PD-1/PD-L1 inhibitor was analyzed, by assessing the lipid volume in each lipid category. Significant variations were determined using Student’s t-tests during the comparison of the patients prior to the commencement of treatment. Asterisks indicate the presence of such significant differences when P -value was lower than 0.05

Back to article page

Lipids in Health and Disease

ISSN: 1476-511X